DE:6BG Stock Latest News
Company AnnouncementsLytix Reports NeoLIPA Phase II Study Met Primary Endpoint3h ago6BG
Company AnnouncementsLytix NeoLIPA Data Selected for ESMO Oral Presentation4d ago6BG
Company AnnouncementsLytix Sets Date for Third-Quarter 2026 Results6d ago6BG
Company AnnouncementsLytix’s NeoLIPA Melanoma Study Reaches Primary Endpoint1w ago6BG
Company AnnouncementsLytix Biopharma Grants Over 1 Million Share Options to Bolster Talent Retention2M ago6BG
Company AnnouncementsLytix Biopharma Chair Boosts Stake With Insider Share Purchase2M ago6BGCompany AnnouncementsLytix Biopharma Secures FDA Backing for Ruxotemitide Registrational Melanoma Study2M ago6BG
Company AnnouncementsLytix Biopharma Wins FDA Backing for Phase III Melanoma Trial of Ruxotemitide2M ago6BG
- Company AnnouncementsLytix Biopharma Backs New Phase II Melanoma Trial Testing Ruxotemitide with Dual Checkpoint Therapy2M ago6BG
Company AnnouncementsLytix Biopharma Sets Date for Q2 2026 Results and Investor Webcast2M ago6BG- Company AnnouncementsLytix Biopharma hires veteran dealmaker as Chief Business Officer to drive oncology partnerships2M ago6BG
Company AnnouncementsLytix Biopharma Grants 1.23 Million Share Options to Strengthen Executive Incentives3M ago6BG
Company AnnouncementsLytix Biopharma’s Ruxotemitide Combo Shows Promise in Tough Cancers at ASCO 20265M ago6BGCompany AnnouncementsLytix Biopharma Advances Ruxotemitide Program as Q1 2026 Results Underscore Oncology Focus5M ago6BG
Company AnnouncementsLytix Biopharma Highlights New Phase II Data Suggesting Systemic Immune Effects of Cancer Drug6M ago6BG- Company AnnouncementsLytix Biopharma’s Lead Cancer Therapy Highlighted in ASCO 2026 Combination Study6M ago6BG
Company AnnouncementsLytix Biopharma Posts Durable Phase II Responses for Ruxotemitide Combo in Refractory Melanoma6M ago6BG
Company AnnouncementsLytix Biopharma Completes Conversion to Public Limited Company7M ago6BG
Company AnnouncementsLytix Biopharma Overhauls Board and Renews Capital Mandate at AGM7M ago6BGCompany AnnouncementsLytix Biopharma Grants Share Options to Board Member Under Incentive Plan7M ago6BG